Reuters logo
BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines
September 25, 2017 / 8:39 PM / a month ago

BRIEF-Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

Sept 25 (Reuters) - Genocea Biosciences Inc

* Genocea announces strategic shift to immuno-oncology and the development of neoantigen cancer vaccines

* Genocea Biosciences Inc - expects to file an investigational new drug (ind) application by early 2018. For ‍Gen-009

* Genocea Biosciences Inc - ‍Genocea is ceasing Gen-003 spending and activities and is reducing its workforce by approximately 40 percent​

* Genocea Biosciences Inc - ‍plans to initiate a phase 1 clinical trial for gen-009 in a range of tumor types in first half of 2018​

* Genocea Biosciences Inc - ‍expects to report initial immunogenicity data in first half of 2019 for gen-009​

* Genocea Biosciences - ‍expects existing cash, cash equivalents sufficient to support operating expenses, capital expenditure requirements to middle of 2018​

* Genocea Biosciences Inc - estimates annualized savings of about $6.5 million, , one-time severance and related costs of about $1.1 million in Q3 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below